In “Doctored,” Charles Piller uncovers evidence that many important Alzheimer’s studies are based on faulty data.

On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.

Leqembi was rejected by an EU panel based on safety data, while Biogen pulled its previous Alzheimer’s treatment from the market entirely based on a lack of uptake. Cassava Sciences is working ...

Take two at bedtime. That’s what the label on the side of the bottle says, and that’s what you’ll do. You want to feel better soon — your health and well-being are important — so you’ll do as you’re ...

Cassava Sciences SAVA, a clinical-stage biotech focusing on developing novel products to detect and treat neurodegenerative diseases, such as Alzheimer’s disease (AD), is expected to report ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...